Communiqués Alumis Inc.

Actions

ALMS

US0223071020

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:01:46 06/10/2026			Varia. 5j.	Varia. 1 janv.
6,790 ^USD	-0,73%		-6,93%	-30,48%

14/09	Transcript : Alumis Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:45 AM
10/09	Les plus fortes hausses en avant-Bourse	MT

Communiqués

04/09	Alumis to Participate in Upcoming September Investor Conferences	AQ
01/09	Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)	AQ
14/08	Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements	AQ
13/08	Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements	AQ
10/08	Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies	AQ
14/05	Alumis : Corporate Presentation - May 2026	PU
14/05	Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements	AQ
13/04	Alumis : Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Data Presentation	PU
30/03	Alumis Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis	AQ
28/03	Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis	AQ
19/03	Alumis : Corporate Presentation - March 2026	PU
19/03	Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements	AQ
18/03	Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting	AQ
02/03	Alumis to Present at the Leerink Partners Global Healthcare Conference	AQ
05/02	Alumis to Participate in Upcoming February Investor Conferences	AQ
12/01	Alumis : Corporate Presentation - January 2026	PU
09/01	Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ
08/01	Alumis : Envudeucitinib ONWARD Phase 3 Plaque Psoriasis Trial Results Event Presentation	PU
08/01	Alumis Announces Pricing of Upsized Public Offering of Common Stock	AQ
06/01	Alumis Announces Proposed Public Offering of Common Stock	AQ
06/01	Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program	GL
05/01	Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis	AQ
03/12	Alumis : Corporate Presentation - November 2025	PU
13/11	Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress	AQ
04/11	Alumis to Participate in Upcoming November Investor Conferences	AQ